Imago BioSciences, Inc. (IMGO)
$36.01
0.00 (0.00%)
Rating:
Recommendation:
-
| Symbol | IMGO |
|---|---|
| Price | $36.01 |
| Beta | 0.000 |
| Volume Avg. | 0.76M |
| Market Cap | - |
| Shares () | - |
| 52 Week Range | 11.56-36.09 |
| 1y Target Est | - |
| DCF Unlevered | IMGO DCF -> | |
|---|---|---|
| DCF Levered | IMGO LDCF -> | |
| ROE | -25.27% | Sell |
| ROA | -25.27% | Sell |
| Operating Margin | - | |
| Debt / Equity | - | |
| P/E | - | |
| P/B | 7.04 | Strong Buy |
Latest IMGO news
About
Download (Excel)Dr. Hugh Young Rienhoff Jr., M.D.
Healthcare
Biotechnology
NASDAQ Global Select
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.